Business Wire

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe ...
EurekAlert!

Electrostatic self-assembled CS/Ti3C2Tx/Co@CNTs composites with gradient carbon structure and wideband microwave absorption

CS/Ti3C2Tx/Co@CNTs composite could obtain the minimum reflection loss (RLmin) of -55.01 dB at the thickness of 3.4 mm and the ...
Analytics India Magazine

How Gradient-Boosting is Quietly Powering India’s Research Push

From groundwater and slopes to carbon sinks, tools like CatBoost are enabling Indian scientists to extract insights and drive ...
Nasdaq

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update

“In the third quarter, we added more Korlym® prescribers and more patients received Korlym treatment than ever before,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer. “Physicians are ...